[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"metabolic-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:metabolic-diseases":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,21,0,[8,49,78,104,137,187,217,277,302,323,349,377,407,432,475,500,526,562,591,617,660],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100054307","phase-2-metabolic-modulation-to-enhance-insulin-sensitivity-and-mitochondrial-function-in-type-1-diabetes-metmod-t1d-100054307",false,"NCT07699380","METabolic MODulation to Enhance Insulin Sensitivity and Mitochondrial Function in Type 1 Diabetes (MetMod-T1D)","MetMod-T1D","Inclusion Criteria:\n\n1. Adults ≥18 years to \\\u003C70 years of age with established T1D (duration ≥1 year)\n2. Currently on insulin therapy (multiple daily injections or insulin pump)\n3. HbA1c \\\u003C9.5%\n4. BMI 18.5-40 kg\u002Fm2\n5. On stable dose of RASB or statin, if indicated\n6. Willing and able to comply with all study procedures\n\nExclusion Criteria:\n\n1. History of pancreatic disease (including pancreatitis) or pancreatic surgery\n2. History of cardiovascular disease or stroke within the past 6 months\n3. History of heart failure per New York Heart Association criteria\n4. History of severe edema or salt restriction requirement\n5. Biliary disease or pathologies that may alter enterohepatic circulation of bile acids\n6. Estimated glomerular filtration rate (eGFR) \\\u003C60 mL\u002Fmin\u002F1.73m²\n7. Liver disease (ALT\u002FAST \\>3x upper limit of normal \\[ULN\\])\n8. Pregnancy, breastfeeding, or planning pregnancy during the study period\n9. Known hypersensitivity to study drug components\n10. Abnormal baseline ECG\n11. Use of off label medications that affect insulin sensitivity within the past 1 month (e.g., metformin, GLP-1RA, SGLT2i, pioglitazone)\n12. Chronic use of anticoagulants\n13. Use of bile acid sequestering agents, inhibitors of bile acid transporters, bile acid derivatives, aluminum-based antacids, probenecid, pan-HDAC inhibitors, phase 2 metabolizing enzymes (e.g., uridine diphosphate glucuronosyl transferases), phase 1 metabolizing enzymes other than cytochrome P450 enzymes (CYPs), and OATP1B3\n14. Use of substrates of CYP1A2, CYP2C8, CYP2B6, CYP3A4, Organic Anion transporter 1, P-glycoprotein, and Breast Cancer Resistance Protein\n15. History of severe hypoglycemia requiring assistance within the past 3 months\n16. History of diabetic ketoacidosis (DKA) within the past 3 months\n17. Personal or family history of breast cancer or ovarian cancer\n18. Current participation in another clinical trial\n19. Any condition(s) found by the study team and confirmed with the Investigator that make it unsafe to participate","ALL","18 Years","69 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The study is a randomized, double-blind, parallel-group clinical trial to examine the effects of 24 weeks of oral AMX0035 (sodium phenylbutyrate + taurursodiol) versus placebo in 60 adults with Type 1 Diabetes (T1D) (n=30 per arm). Enrollment will be distributed equally between the University of Washington and Amsterdam University Medical Center\u002FDiabetes Center Amsterdam. Participants will be recruited through diabetes research registries, local T1D clinics, and community outreach.",[27,28,29,30,31,32,33,34,35],"Type 1 Diabetes (T1D)","Metabolic Diseases","Glucose Metabolism Disorders","Endocrine System Diseases","Autoimmune Diseases","Immune System Diseases","Diabetes Melletus, Type 1","Nutritional and Metabolic Diseases","Combination Therapy","RECRUITING","2026-07-09",{"date":39,"type":40},"2026-07-13","ACTUAL",{"date":42,"type":21},"2026-06",{"date":44,"type":21},"2029-12",{"name":46,"class":47},"University of Washington","OTHER",2,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100259000","genetic-and-metabolic-disease-in-children-100259000","NCT02650622","Genetic and Metabolic Disease in Children","Genetic Regulators of Metabolism and Development in Children","Inclusion criteria of Cohort 1- Newborn:\n\n* Subjects aged 1-2 days\n* Subjects with gestational age 37-42 weeks\n* Subjects with stable clinical status (admitted to normal newborn nursery)\n\nInclusion criteria of Cohort 2 - Older children:\n\n• Subjects aged 0-18 years\n\nInclusion criteria of Cohort 3 - Diseased children:\n\nSubjects (no age limit) with ANY phenotype as below:\n\n* Confirmed metabolic or genetic diseases\n* Suspected metabolic or genetic diseases\n* Episodic metabolic decompensation (e.g. hypoglycemia, hyperammonemia, metabolic acidosis)\n* Developmental regression\n* Major congenital malformation\n* Other unexplained symptoms of potential genetic origin\n\nExclusion criteria of Cohort 1 - Newborn:\n\n* Subjects with gestational age \\\u003C37 weeks or \\>42 weeks\n* Subjects with overt signs of metabolic dysfunction, distress or genetic diseases including hypoglycemia, hyperglycemia, sepsis\u002Fshock, hypoxemia, or major congenital malformation\n* Subjects with mothers whose pregnancies were complicated by gestational diabetes, gestational hyperglycemia, gestational hypertension, preeclampsia, or any other major disorders.\n\nExclusion criteria of Cohort 2 - Older children:\n\n* Subjects with confirmed metabolic or genetic diseases\n* Subjects with suspected metabolic or genetic diseases\n* Subjects with episodic metabolic decompensation (e.g. hypoglycemia, hyperammonemia, metabolic acidosis)\n* Subjects with developmental regression\n* Subjects with major congenital malformation\n\nExclusion criteria of Cohort 3 - Diseased children No.","1 Day",{"count":58,"type":21},1550,"OBSERVATIONAL","This is a prospective, non-randomized, non-blinded observational study. The overarching goal is to discover new disease-associated genes in children, while establishing a specific focus on disorders where molecular characterization is most likely to lead to novel therapies. This study will merge detailed phenotypic characterization of patients presenting to the Pediatric Genetics and Metabolism Division in the Department of Pediatrics\u002FChildren's Medical Center at Dallas and collaborating clinics with Next-Generation sequencing techniques to identify disease-producing mutations. The primary objective of the study is to identify novel pathogenic mutations in children with rare Mendelian disorders. A secondary objective of the study is to establish normative ranges of a large number of metabolites from healthy newborns and older children.",[62,28],"Genetic Diseases",[64,65,66,67],"Metabolism","Genetics","Metabolomics","Genomics","2026-06-30",{"date":70,"type":40},"2026-07-02",{"date":72,"type":40},"2015-06",{"date":74,"type":21},"2030-05",{"name":76,"class":47},"University of Texas Southwestern Medical Center",1,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":89,"conditions":90,"keywords":91,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":77},"100620356","evaluation-of-therapeutic-adherence-among-patients-followed-in-the-department-of-hereditary-metabolic-diseases-at-necker-hospital-100620356","NCT07356557","Evaluation of Therapeutic Adherence Among Patients Followed in the Department of Hereditary Metabolic Diseases at Necker Hospital","OBSERVANCE MHM","Inclusion Criteria:\n\n* All patients followed in the Hereditary Metabolic Diseases department of Necker Hospital during their visit to the department for their usual care and having a specific daily oral medication treatment.\n* Children aged at least 7 years and adolescents\u002Fyoung adults\n* Holders of parental authority and children or adolescents or adults' patients informed and consenting to participate in the study\n\nExclusion Criteria:\n\n* Metabolic disease without oral medication (intravenous treatments, amino acid mixtures, and dietary regimens are not evaluated).\n* Patient and parents not proficient in French.\n* Refusal by the patient's holders of parental authority or adult patient to participate in the study and\u002For refusal of the child\u002Fadolescent.","7 Years","20 Years",{"count":88,"type":21},200,"The purpose of this study is to evaluate treatment adherence among patients followed in the Department of Inherited Metabolic Diseases at Necker Hospital, in order to assess the need for implementing a therapeutic education workshop focused on medication adherence.",[28],[92,93,94,95],"Metabolic disease","Daily oral drug treatment","Medication adherence","Therapeutic education workshop","2026-06-29",{"date":68,"type":40},{"date":99,"type":40},"2026-02-23",{"date":101,"type":21},"2028-02-23",{"name":103,"class":47},"Assistance Publique - Hôpitaux de Paris",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":115,"conditions":116,"keywords":120,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":133,"leadSponsor":135,"locationsCount":77},"100639957","specificities-of-atypical-non-autoimmune-diabetes-anaid-in-the-french-west-indies-100639957","NCT07576374","Specificities of Atypical Non AutoImmune Diabetes (ANAID) in the French West Indies","Epidemiological, Clinical, Biological and Genetic Specificities of Atypical Non-AutoImmune Diabetes (ANAID) in the French West Indies","DiAGeNA","Inclusion Criteria:\n\nPhenotypic criteria :\n\nSubjects from Indian or African Ancestry self-declared\n\nAge criteria at diagnosis:\n\nEarly onset of diabetes: patient aged between 18 and 47 years at the time of diagnosis of diabetes Clinical criteria: at least 2 criteria Labeled type 2 diabetic\n\nPatient hospitalized for:\n\nKetoacid decompensation Significant weight loss (more than 10% in less than 6 months) without obvious etiology Lipodystrophic \u002F lipoatrophic appearance Presence of an associated myopathy or deafness Presence of early inaugural nephropathy or within 3 years after diagnosis Presence of early inaugural heart disease or within 3 years after diagnosis Poor response to non-insulin treatments despite good adherence\n\nBiological criteria:\n\nAbsent T1D autoantibodies:\n\nAnti-islet antibodies (ICA) Anti-IA2 antibodies Anti-insulin antibodies Anti-ZnT8 antibodies Anti-GAD antibodies\n\nOther criteria:\n\nInformed consent signed by the patient\n\nExclusion Criteria:\n\nType 1 diabetes (T1D) Presence of T1D antibodies Secondary diabetes (pancreas diseases, endocrine diseases, drug intake, infection) Other associated autoimmune pathologies Pregnancy Refusal to participate","47 Years",{"count":114,"type":21},118,"Genetics variants could be involved in atypical non-autoimmune diabetes revealed by ketoacidosis. The objective of this research will be to determine the relationships between the genetic variants already described in known monogenic diabetes or identified as involved in glucose metabolism and its regulation, in insulin signaling pathways or in insulin secretion itself in subjects of African and Indian ancestry with atypical forms of non autoimmune diabetes.",[28,117,118,119,29],"Diabetes Mellitus (Type 2)","Genetic Variation","Genetic Profile",[121,122,123,124,125,126,127],"Genetic diagnosis","Monogenic diabetes","Exome sequencing","Pathogenic variant","Ketoacidosis","Afro-Caribbean","African and Indian ancestry","NOT_YET_RECRUITING","2026-05-04",{"date":131,"type":40},"2026-05-08",{"date":42,"type":21},{"date":134,"type":21},"2029-09",{"name":136,"class":47},"Centre Hospitalier Universitaire de la Guadeloupe",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":144,"sex":145,"minAge":146,"maxAge":147,"enrollmentInfo":148,"targetDuration":4,"studyType":22,"phases":150,"briefSummary":152,"conditions":153,"keywords":170,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":77},"100634052","early-pregnancy-lifestyle-and-glucose-patterns-a-substudy-of-tofffy-100634052","NCT07534670","Early Pregnancy Lifestyle and Glucose Patterns: A Substudy of TOFFFY","Early-Pregnancy Chronobehavioural Profiles and Continuous Glucose Dynamics: A Nested Randomised Pilot Study of TOFFFY","Inclusion Criteria:\n\n* Enrolled in the Towards Optimal Fertility, Fathering and Fatherhood studY (TOFFFY) (NCT06293235)\n* Females who are currently pregnant and with viable intrauterine pregnancy at ≤13 weeks gestation at enrolment\n\nExclusion Criteria:\n\n* Females with pre-existing diabetes mellitus (Type 1 or Type 2) and\u002For chronic medical conditions affecting glucose metabolism\n* Females who are taking medications known to significantly affect glucose metabolism\n* Females with multiple pregnancy (e.g., twins or higher-order gestation)\n* Females who are unable to comply with study procedures, including: Inability to use smartphone-based applications and inability to wear wrist actigraphy device",true,"FEMALE","21 Years","39 Years",{"count":149,"type":21},140,[151],"NA","The goal of this clinical trial is to examine how daily behavioral patterns in early pregnancy, including sleep, physical activity, and meal timing, influence continuous glucose dynamics and subsequent risk of gestational diabetes mellitus (GDM) in pregnant women without pre-existing diabetes.\n\nThe main questions it aims to answer are:\n\n1. Do early-pregnancy chronobehavioral patterns (e.g., irregular sleep, night eating, and unstable rest-activity rhythms) relate to continuous glucose patterns measured using continuous glucose monitoring (CGM)?\n2. Can early behavioral and CGM-derived measures predict glucose regulation and metabolic outcomes later in pregnancy (24-28 weeks)?\n3. Does real-time self-monitoring using wearable devices and food logging improve glycemic outcomes compared to usual care?\n\nThis study is a prospective, nested randomized pilot trial embedded within the ongoing Towards Optimal Fertility, Fathering and Fatherhood studY (TOFFFY) cohort (NCT06293235) at KK Women's and Children's Hospital, Singapore. A total of 140 pregnant women without pre-existing diabetes, recruited at ≤13 weeks gestation, will be randomized in a 1:1 ratio to either a pilot arm (wearable-based self-monitoring) or a control arm (usual care).\n\nParticipants in the pilot arm (n=70) will undergo intensive behavioral and metabolic monitoring over a 14-day period in early pregnancy, including continuous glucose monitoring using a CGM device, wrist actigraphy to assess sleep-wake and rest-activity patterns, and an AI-supported mobile application to record meal timing and dietary intake. Participants will have real-time access to their glucose data and behavioral feedback, enabling self-monitoring and potential behavioral adjustments.",[154,155,156,157,158,159,160,161,162,163,164,165,166,167,28,168,169],"Continuous Glucose Monitoring","Diabetes, Gestational","Diet During Pregnancy","Meal Time","Actigraphy","Pregnancy","Glucose Intolerance During Pregnancy","Gestational Diabetes Mellitus in Pregnancy","Circadian Rhythm","Sleep","Chronobiology","Wearable Electronic Devices","Mobile Applications","Blood Glucose Profile","Randomized Controlled Trial","Pilot Study",[171,172,173,174,175,176],"Risk factor","Lifestyle","Early pregnancy","Chrono-disruptive behaviours","Maternal health","Lifestyle intervention","2026-04-22",{"date":179,"type":40},"2026-04-27",{"date":181,"type":21},"2026-05-01",{"date":183,"type":21},"2027-06-30",{"name":185,"class":186},"KK Women's and Children's Hospital","OTHER_GOV",{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":191,"acronym":192,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":194,"enrollmentInfo":195,"targetDuration":197,"studyType":59,"phases":4,"briefSummary":198,"conditions":199,"keywords":203,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":77},"100635008","study-on-construction-of-whole-lifecycle-cohort-big-data-management-and-clinical-prognosis-of-cardio-renal-metabolic-ckm-syndrome-100635008","NCT07547098","Study on Construction of Whole Lifecycle Cohort, Big Data Management and Clinical Prognosis of Cardio-Renal-Metabolic (CKM) Syndrome","CKM-LCBP","Inclusion Criteria:\n\n* Age 18 years or older.\n* Inpatient record available at the First Affiliated Hospital of Fujian Medical University with retrievable identifiers for data linkage.\n* Cardiovascular disease, kidney disease, metabolic disease, or key examination\u002Flaboratory information supporting CKM phenotyping.\n* Willingness to participate and provision of written informed consent.\n* Ability to complete baseline assessment and follow-up.\n* Full civil capacity and ability to understand study information.\n\nExclusion Criteria:\n\n* Refusal to provide written informed consent.\n* Severe psychiatric disease or cognitive impairment precluding participation.\n* End-stage disease with expected survival less than 1 year.\n* Long-term absence more than 6 months preventing reliable follow-up.\n* Participation in another clinical study that may interfere with endpoint adjudication.\n* Missing key fields preventing linkage of examinations, imaging, and outcomes.","80 Years",{"count":196,"type":21},8000,"5 Years","This is a single-center observational registry study aiming to establish a structured clinical and multimodal imaging database for cardiovascular-kidney-metabolic (CKM) populations and to support lifecycle follow-up and outcome management. Adult patients aged 18-80 years with cardiovascular, kidney, and\u002For metabolic diseases or key data for CKM phenotyping will be enrolled at the First Affiliated Hospital of Fujian Medical University. The study integrates retrospective data entry and prospective follow-up, including clinical records, laboratory tests, medications, electrocardiography, echocardiography, vascular function assessment, carotid and abdominal ultrasound, bone density, coronary CTA and post-processing data. The primary outcome is the first occurrence of a cardiorenal composite endpoint. Participants will be followed for up to 5 years through active annual follow-up and passive monthly data updates to support risk stratification, real-world evidence generation, and CKM management pathway optimization.",[200,201,28,202],"Cardiovascular Diseases (CVD)","Chronic Kidney Disease","Cardiovascular-kidney-metabolic Syndrome",[204,205,206,207],"CKM syndrome","Cardiovascular-Kidney-Metabolic","Patient registry","Real-world data","2026-04-19",{"date":210,"type":40},"2026-04-23",{"date":212,"type":40},"2026-03-01",{"date":214,"type":21},"2031-02-28",{"name":216,"class":47},"First Affiliated Hospital of Fujian Medical University",{"id":218,"slug":219,"hasResults":11,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":4,"eligibilityCriteria":223,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":224,"enrollmentInfo":225,"targetDuration":4,"studyType":22,"phases":226,"briefSummary":228,"conditions":229,"keywords":249,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":276},"100567749","phase-3-a-phase-3-study-of-ntla-2001-in-attrv-pn-100567749","NCT06672237","A Phase 3 Study of NTLA-2001 in ATTRv-PN","MAGNITUDE-2: A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN)","Inclusion Criteria:\n\n* Diagnosis of ATTRv-PN\n* Karnofsky Performance Status (KPS) ≥ 60\n\nExclusion Criteria:\n\n* Other causes of amyloidosis (amyloidosis caused by non-TTR protein)\n* Other known causes of sensorimotor or autonomic neuropathy\n* Diabetes mellitus\n* New York Heart Association Class III or IV heart failure\n* Liver failure\n* Hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection\n* Prior receipt of a TTR silencer (Small interfering RNA (siRNA) or Antisense oligonucleotides (ASOs))\n* Estimated Glomerular Filtration Rate \\\u003C 30 mL\u002Fmin\u002F1.73 m2\n* Unable or unwilling to take vitamin A supplementation for the duration of the study\n* History of liver disease","85 Years",{"count":20,"type":21},[227],"PHASE3","This study will be conducted to evaluate the efficacy and safety of a single dose of nexiguran ziclumeran (NTLA-2001) compared to placebo in participants with ATTRv-PN.",[230,231,232,233,234,235,236,237,238,239,240,241,242,243,244,245,246,247,248,28],"Neuromuscular Disease","Neuromuscular Diseases (NMD)","Neurodegenerative Disease","Neurodegenerative Disease, Hereditary","Neurodegenerative Diseases","Neuromuscular Diseases","Nerve Disorders","Nervous System Disease","Nervous System Diseases","Genetic Disease, Inborn","Amyloidosis, Familial","Amyloidosis, Hereditary","Amyloidosis","Polyneuropathies","Amyloid Neuropathies","Amyloid Neuropathies, Familial","Peripheral Nervous System Disease","Peripheral Nervous System Diseases","Metabolism, Inborn Errors",[250,242,251,252,253,254,255,256,257,258,259,260,261,262,263,264,265],"TTR","Polyneuropathy","NTLA-2001","ATTR","ATTR-PN","ATTRv-PN","Transthyretin","TTR-mediated amyloidosis","Amyloidosis, hereditary","Amyloidosis, hereditary, transthyretin-related amyloidosis","Transthretin amyloid polyneuropathy","TTR PN","TTR polyneuropathy","nexiguran ziclumeran","nex-z","CRISPR","2026-04-13",{"date":268,"type":40},"2026-04-16",{"date":270,"type":40},"2024-11-22",{"date":272,"type":21},"2028-08",{"name":274,"class":275},"Intellia Therapeutics","INDUSTRY",14,{"id":278,"slug":279,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":281,"acronym":282,"eligibilityCriteria":283,"healthyVolunteers":144,"sex":16,"minAge":17,"maxAge":284,"enrollmentInfo":285,"targetDuration":4,"studyType":22,"phases":287,"briefSummary":289,"conditions":290,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":77},"100516333","phase-4-glucose-mgh-genetic-links-understood-through-challenge-with-oral-semaglutide-exposure-at-mgh-100516333","NCT06003153","GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH","GLUCOSE-MGH","Inclusion Criteria:\n\n1. Males or non-pregnant females\n2. Ages 18-65 (inclusive)\n3. Able\u002Fwilling to give consent\n4. Span the metabolic range between normal glycemia and pre-diabetes (fasting glucose of 100-125 mg\u002FdL based on chart review of existing laboratory data)\n\nExclusion Criteria:\n\n1. Currently taking medications or intending to take medications for diabetes\n2. Currently taking medications or intending to take medications that affect glycemic parameters, such as glucocorticoids, growth hormone, or fluoroquinolones\n3. Personal history of intestinal malabsorption, bariatric surgery, celiac disease, gallbladder disease, or pancreatitis\n4. Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2\n5. Estimated glomerular filtration rate (eGFR) \\\u003C60 ml\u002Fmin\u002F1.73 m2 per the Modification of Diet in Renal Disease equation\n6. History of cirrhosis and\u002For aspartate aminotransferase or alanine aminotransferase more than 3x upper limit of normal\n7. Dietary restrictions preventing consumption of a MMTT\n8. Women who are pregnant, nursing, or at risk of becoming pregnant\n9. Participation in other interventional studies during the current study","65 Years",{"count":286,"type":21},125,[288],"PHASE4","The goal of this research study is to evaluate the pathophysiologic mechanisms by which genetic variation impacts response to an FDA-approved medication commonly used to treat type 2 diabetes called oral semaglutide (Rybelsus) and to characterize the physiological response to a mixed meal tolerance test (MMTT) before and after a 14-day treatment with oral semaglutide. The investigators will do this by measuring factors in the blood, such as sugars, fats, metabolites, and proteins, after eating a standardized breakfast meal at the first visit and after taking 14 doses of oral semaglutide over two weeks before the second study visit. The food (mixed meal breakfast) we will be studying is specially prepared to contain a set amount of protein, carbohydrates, and fat. The investigators hypothesize that understanding how the acute biochemical response to oral semaglutide differs by genetic variation will generate insight into drug mechanisms and type 2 diabetes pathophysiology.",[291,28,292],"Genetic Predisposition","Type 2 Diabetes","2026-04-03",{"date":295,"type":40},"2026-04-06",{"date":297,"type":40},"2024-03-12",{"date":299,"type":21},"2027-05-31",{"name":301,"class":47},"Massachusetts General Hospital",{"id":303,"slug":304,"hasResults":11,"nctId":305,"briefTitle":306,"officialTitle":306,"acronym":4,"eligibilityCriteria":307,"healthyVolunteers":144,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":308,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":310,"conditions":311,"keywords":312,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":321,"locationsCount":77},"100570638","magnetic-resonance-imaging-in-metabolic-diseases-100570638","NCT06709846","Magnetic Resonance Imaging in Metabolic Diseases","Inclusion Criteria:\n\n* patients with metabolic diseases OR\n* healthy control participants without metabolic diseases\n* written consent\n\nExclusion Criteria:\n\n* History of traumatic brain injuries\n* preterm birth (≤34th week of pregnancy) of the study participant\n* history of brain surgery\n* structural brain changes (e.g., tumors, congenital abnormalities, etc.)\n* neurological developmental disorders (e.g., autism spectrum disorders, learning disabilities, intellectual disability)\n* epilepsy,\n* drug addiction\n* other severe neurological or severe psychiatric disorders (e.g., schizophrenia\n* pregnancy\n* acute clinically relevant inflammatory diseases\n* acute systemic or local infections\n* severe or etiologically unclear diseases depending on the principle investigators judgement\n* pre-existing intellectual impairment\n* significant limitations in language comprehension\n* absence of written consent\n* general exclusion criteria for MRI imaging (e.g., pacemaker systems, neurostimulators, cochlear implants)",{"count":309,"type":21},126,"This study aims to leverage structural, functional, and metabolic magnetic resonance imaging (MRI) of the brain to identify imaging features that correlate with clinical parameters. It is hypothesized that individuals with metabolic diseases exhibit distinct functional and structural brain differences compared to healthy controls. These differences may evolve over time due to changes in whole-body metabolism or body weight, influenced by factors such as the natural progression of the disease or therapeutic interventions. Additionally, potential brain changes may correlate with body composition metrics, such as the fat content of specific body compartments.\n\nThis is a prospective, single-center study conducted at Ulm University Hospital, designed to track the clinical and imaging histories of patients with metabolic diseases and compare them to healthy individuals. Eligible participants include adults (aged 18 and older) capable of providing informed consent. Recruitment will occur through routine clinical care or existing research studies. To provide a comprehensive understanding, the study will include both cross-sectional analyses and longitudinal follow-up of participants, integrating repeated assessments during routine medical visits.",[28],[28,313,314],"Magnetic Resonance Imaging","Body Composition","2026-02-12",{"date":317,"type":40},"2026-02-13",{"date":319,"type":40},"2025-02-08",{"date":44,"type":21},{"name":322,"class":47},"University of Ulm",{"id":324,"slug":325,"hasResults":11,"nctId":326,"briefTitle":327,"officialTitle":328,"acronym":4,"eligibilityCriteria":329,"healthyVolunteers":144,"sex":16,"minAge":330,"maxAge":331,"enrollmentInfo":332,"targetDuration":4,"studyType":22,"phases":334,"briefSummary":335,"conditions":336,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":341,"startDateStruct":343,"completionDateStruct":345,"leadSponsor":347,"locationsCount":77},"100457421","effects-of-daily-beef-intake-as-a-component-of-a-heart-healthy-diet-on-cellular-zinc-100457421","NCT05236374","Effects of Daily Beef Intake, as a Component of a Heart-Healthy Diet on Cellular Zinc","Effects of Daily Beef Intake, as a Component of a Heart-Healthy Diet, on Cellular Zinc Status and Vascular Function in Older Adults","Inclusion Criteria:\n\n* Male or postmenopausal female 55-70 years of age\n* Women: lack of menses for at least two years.\n* Subject is willing and able to comply with the study protocols.\n* Subject is willing to participate in all study procedures\n* Self-reported stable dose of prescribed medications for a minimum of 6 months\n* BMI 18.5 - 29.9 kg\u002Fm2\n\nExclusion Criteria:\n\n* Self-reported use of daily anticoagulation agents including aspirin, NSAIDs\n* Prescribed metaformin, statins or medications known to interfere with zinc, protein, or lipid metabolism\n* Vegan, Vegetarians, food faddists or those consuming a non-traditional diet (e.g. Adkins, Keto, Paleo, etc.)\n* Fruit consumption ≥ 3 cups\u002Fday\n* Regular consumption of strawberries (2-3 servings\u002Fweek)\n* Vegetable consumption ≥ 4 cups\u002Fday\n* Coffee\u002Ftea ≥ 3 cups\u002Fday\n* Dark chocolate ≥ 3 oz\u002Fday\n* Alcohol intake greater than 2 drinks in a day for men, or 1 drink in a day for women.\n* Self-reported restriction of physical activity due to a chronic health condition\n* Self-reported chronic\u002Froutine high intensity exercise\n* Self-reported diabetes\n* Blood pressure ≥ 140\u002F90 mm Hg\n* Self-reported renal or liver disease\n* Self-reported heart disease, which includes cardiovascular events and stroke\n* Peripheral artery disease Raynaud's syndrome or disease\n* Inability to properly place or wear the PAT probes or abnormal measurements on pre-screening PAT\n* Self-reported cancer within past 5 years\n* Self-reported malabsorption\n* Unwillingness to stop any supplement use six weeks prior to study initiation, including multivitamin\u002Fmineral, powders, herbal, plant or botanical, pro- and prebiotics, and oil supplements.\n* Smoking, vaping, cannabis use\n* Current enrollee in a clinical research study.","55 Years","70 Years",{"count":333,"type":21},20,[151],"The objective of the current study is to test the overarching hypothesis that the beef nutritive matrix is uniquely suited to direct dietary zinc to cellular compartments for improved metabolic function, leading to a greater effect on health outcomes. Specifically, whether beef, as a component of a healthy meal, will promote the absorption of zinc into cells, where the zinc will have greater effects on zinc-dependent metabolic processes supporting cardiovascular health. To maximize the observability of these beef-related effects, individuals who are 55- to 70-year-old who generally have a higher risk of zinc deficiency and cardiovascular disease will be enrolled.",[337,338,28,339],"Zinc Deficiency","Inflammation","Vascular Diseases","2026-02-04",{"date":342,"type":40},"2026-02-09",{"date":344,"type":40},"2022-10-01",{"date":346,"type":21},"2026-12-31",{"name":348,"class":47},"University of California, Davis",{"id":350,"slug":351,"hasResults":11,"nctId":352,"briefTitle":353,"officialTitle":354,"acronym":355,"eligibilityCriteria":356,"healthyVolunteers":144,"sex":16,"minAge":17,"maxAge":357,"enrollmentInfo":358,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":360,"conditions":361,"keywords":363,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":376},"100619339","landscape-of-gout-in-french-polynesia-100619339","NCT07343336","Landscape of Gout in French Polynesia.","FENUA-METABOGOUT : Genetic Landscape of Gout, Inflammation and Metabolic Diseases in French Polynesia.","METABOGOUT","Inclusion Criteria:\n\nAll participants:\n\n* Age between 18 and 75 years old inclusive\n* Signature of informed consent\n* Fasting for the collection of biological samples\n* Declared Polynesian ancestry\n* Affiliated to a social security scheme\n\nGeneral population group :\n\n* Not having participated to the 2021 TOPATA study\n* Visiting a general practitioner (for whatever reason)\n\nGout Group :\n\n* Managed at the rheumatology clinic of the Taaone Hospital Centre (CHT) in Papeete by Dr Baptiste Gérard.\n\nTophaceous gout sub-group:\n\n* Present with tophaceous gout.\n\nGout crisis subgroup:\n\n* Be within 48 hours of the onset of a gout attack\n* Agree to return 1 week after inclusion for the second blood and urine sample.\n\n  2021 follow-up group:\n* To have been included in the TOPATA study in 2021\n* Have taken the genetic and biological samples that generated the genetic and serum urate data for the 2021 study\n* Have hyperuricaemia without signs of gout OR without hyperuricaemia or gout at the time of inclusion in TOPATA\n\nExclusion Criteria:\n\nAll participants :\n\n* Refusal or inability to understand or give consent\n* Physical inability to follow and respect the protocol\n* 1st degree relative\\*,\n* Person under guardianship or trusteeship\n* Pregnant or breast-feeding woman\n\n  \\* If several relatives from the same household are eligible to participate, only one person may be included in the study. The choice is left to the discretion of the investigator or the first person met. However, both members of a couple (e.g. husband and wife) may participate.\n* General population group :\n* Unable to return for sampling if required.\n* Gout group :\n* Person wearing a knee prosthesis\n* People suffering from other inflammatory rheumatic diseases","75 Years",{"count":359,"type":21},2750,"The aim of this research is to characterise the genetic and molecular landscape of gout, inflammation and metabolic diseases, as well as the associated molecular, anthropomorphic and pathological characteristics.",[362,28,338],"Gout Disease",[364,365,366],"Gout disease","metabolic disease","inflammation","2026-01-06",{"date":369,"type":40},"2026-01-15",{"date":371,"type":40},"2025-09-02",{"date":373,"type":21},"2027-09",{"name":375,"class":47},"Lille Catholic University",6,{"id":378,"slug":379,"hasResults":11,"nctId":380,"briefTitle":381,"officialTitle":382,"acronym":4,"eligibilityCriteria":383,"healthyVolunteers":144,"sex":16,"minAge":384,"maxAge":385,"enrollmentInfo":386,"targetDuration":4,"studyType":22,"phases":388,"briefSummary":389,"conditions":390,"keywords":394,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":399,"startDateStruct":401,"completionDateStruct":403,"leadSponsor":405,"locationsCount":77},"100609511","effects-of-hiit-vs-tre-on-type-2-diabetes-risk-100609511","NCT07215533","Effects of HIIT vs. TRE on Type 2 Diabetes Risk","Differential Effects of HIIT vs. TRE on Type 2 Diabetes Risk in Youth and Younger Adults","Inclusion Criteria:\n\n* Adolescents (age 14-17 years old with sex- and race-specific BMI percentile ≥85th) and young adults with overweight and obesity (age 18 to 30 years old with BMI ≥25 kg\u002Fm2)\n\nExclusion Criteria:\n\n* Chronic medical conditions: heart disease, arrhythmias, diabetes, thyroid disease, bleeding disorder, history of pulmonary disease, hypertension, hepatorenal disease, musculoskeletal disorder, neuromuscular\u002Fneurological disease, autoimmune disease, cancer, peptic ulcers, anemia, or chronic infection (HIV).\n* Have taken any heart, pulmonary, thyroid, anti-hyperlipidemic, hypoglycemic, anti- hypertensive, endocrinologic (e.g., thyroid, insulin, etc.), emotional\u002Fpsychotropic (e.g., Prednisone, Ritalin, Adderall), neuromuscular\u002Fneurological, or androgenic medications (anabolic steroids).\n* Have a pacemaker.","14 Years","30 Years",{"count":387,"type":21},40,[151],"The primary aim of this randomized controlled trial is to examine the effects of a 4-week high-intensity interval training (HIIT) and time-restricted eating (TRE) intervention on cardiometabolic biomarkers in adolescents and young adults.",[391,28,392,393],"Obesity and Type 2 Diabetes","High-intensity Interval Training","Time-restricted Eating",[392,393,395,292,396,397],"Obesity","Youth","Young Adults","2025-10-08",{"date":400,"type":40},"2025-10-10",{"date":402,"type":40},"2024-03-15",{"date":404,"type":21},"2025-12-30",{"name":406,"class":47},"Syracuse University",{"id":408,"slug":409,"hasResults":11,"nctId":410,"briefTitle":411,"officialTitle":411,"acronym":4,"eligibilityCriteria":412,"healthyVolunteers":144,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":413,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":415,"conditions":416,"keywords":421,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":423,"lastUpdatePostDateStruct":424,"startDateStruct":426,"completionDateStruct":428,"leadSponsor":430,"locationsCount":77},"100608742","sarcopenia-metabolic-diseases-and-integrated-aging-longitudinal-evaluation-smile-100608742","NCT07205510","Sarcopenia, Metabolic Diseases, and Integrated Aging Longitudinal Evaluation (SMILE)","Inclusion Criteria:\n\nAdults aged 18 and over\n\nExclusion Criteria:\n\n1. Does not cooperate in signing the informed consent form;\n2. Does not possess legal capacity;\n3. In a state of loss of consciousness;\n4. Suffering from severe mental illness, unable to communicate normally;\n5. The researcher believes that the subject has a disease that affects the assessment of results and is unsuitable for inclusion.",{"count":414,"type":21},10000,"This study aims to establish an ambispective cohort platform centered on the pathological axis of \"sarcopenia-metabolic disorders-aging progression\", integrating multimodal data including demographic characteristics, lifestyle factors, clinical phenotypes, laboratory tests, medical imaging, and biospecimens. Namely 'Sarcopenia, Metabolic Diseases, and Integrated Aging Longitudinal Evaluation (SMILE)'.",[417,28,418,419,420],"Sarcopenia","All-cause Mortality","Aging","Cardiometabolic Diseases",[417,28,419,422,420],"All-cause mortality","2025-09-25",{"date":425,"type":40},"2025-10-03",{"date":427,"type":40},"2020-12-01",{"date":429,"type":21},"2040-12-31",{"name":431,"class":47},"RenJi Hospital",{"id":433,"slug":434,"hasResults":11,"nctId":435,"briefTitle":436,"officialTitle":437,"acronym":4,"eligibilityCriteria":438,"healthyVolunteers":11,"sex":439,"minAge":4,"maxAge":4,"enrollmentInfo":440,"targetDuration":4,"studyType":22,"phases":442,"briefSummary":443,"conditions":444,"keywords":446,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":466,"startDateStruct":468,"completionDateStruct":470,"leadSponsor":472,"locationsCount":474},"100455264","phase-2-a-multi-cohort-study-of-safety-efficacy-pk-and-pd-of-gnr-055-in-patients-with-mucopolysaccharidosis-type-ii-100455264","NCT05208281","A Multi-cohort Study of Safety, Efficacy, PK and PD of GNR-055 in Patients With Mucopolysaccharidosis Type II","Multicenter, Open-Label, Multi-cohort Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Drug Product GNR 055 (JSC \"GENERIUM\", Russia) in Patients With Mucopolysaccharidosis Type II","Inclusion Criteria:\n\n* Signed inform consent;\n* Verified diagnosis of MPS II (Hunter syndrome);\n* Naïve patients or patients who have received standard ERT whit idursulfase products;\n* No contraindications for lumbar puncture as judged by the Investigator;\n* Willingness and ability to follow study procedures.\n\nExclusion Criteria:\n\n* Clinically pronounced hypersensitivity to ID2S or any other component of the drug product;\n* History of hematopoietic stem cell transplantation (HSCT) or bone marrow transplantation;\n* Implanted or external non-removable metal devices, a cardiac pacemaker, or other objects sensitive to the magnetic field that may pose a danger to both the wearer and the correct operation of magnetic resonance imaging (MRI) equipment;\n* Concomitant diseases and conditions that, in the Investigator's opinion, can put at risk the patient's safety during his\u002Fher participation in the study, or which will influence the safety data analysis in case of the disease\u002Fcondition exacerbation during the study.","MALE",{"count":441,"type":21},32,[24,227],"This is phase 2\u002F3 study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of the investigational product GNR-055 in MPS II (Hunter syndrome) patients of different age groups.",[445,28],"Mucopolysaccharidosis Type II",[447,448,28,449,450,451,452,453,454,455,456,457,458,459,460,461,238,462,463,464],"Mucopolysaccharidosis type II","Cognitive Dysfunction","Lysosomal Storage Diseases","Neurocognitive Disorders","Metabolism, Inborn","Genetic Diseases, Inborn","Neurobehavioral Manifestations","Neurologic Manifestations","Genetic Diseases, X-Linked","Hunter syndrome","Iduronate-2-sulfatase","Modified I2S protein","Connective Tissue Diseases","Mental Disorders","Intellectual Disability","Heredodegenerative Disorders, Nervous System","Cognition Disorders","Mental Retardation, X-Linked","2025-07-28",{"date":467,"type":40},"2025-07-30",{"date":469,"type":40},"2021-11-30",{"date":471,"type":21},"2028-03",{"name":473,"class":275},"AO GENERIUM",5,{"id":476,"slug":477,"hasResults":11,"nctId":478,"briefTitle":479,"officialTitle":480,"acronym":481,"eligibilityCriteria":482,"healthyVolunteers":144,"sex":16,"minAge":483,"maxAge":194,"enrollmentInfo":484,"targetDuration":4,"studyType":22,"phases":486,"briefSummary":487,"conditions":488,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":492,"startDateStruct":494,"completionDateStruct":496,"leadSponsor":498,"locationsCount":77},"100548749","nicotinamide-riboside-supplementation-and-exercise-training-to-promote-healthy-longevity-100548749","NCT06425042","Nicotinamide Riboside Supplementation and Exercise Training to Promote Healthy Longevity","Boosting the NAD+ Levels in Older Individuals Via Nicotinamide Riboside Supplementation and Exercise Training to Promote Metabolic Health","RESTORENAD","Inclusion Criteria:\n\n* Participants are able to provide signed and dated written informed consent prior to any study specific procedures\n* Aged ≥ 60 and ≤ 80 years\n* Body mass index (BMI) 25 - 35 kg\u002Fm2\n* Stable dietary habits (no weight loss or gain \\> 5 kg in the past 3 months)\n* No signs of active cardiovascular disease, liver or kidney malfunction\n\nExclusion Criteria:\n\n* Patients with congestive heart failure and and\u002For severe renal and or liver insufficiency\n* Uncontrolled hypertension\n* Any contra-indication for MRI scanning\n* Alcohol consumption of \\> 3 servings per day for man and \\>2 servings per day for woman\n* Smoking\n* Unstable body weight (weight gain or loss \\> 5kg in the last 3 months)\n* Engagement in structured exercise activities \\> 2 hours a week\n* Previous enrolment in a clinical study with an investigational product during the last 3 months or as judged by the Investigator which would possibly hamper our study results\n* Use of food supplements containing NR or Resveratrol (similar working mechanisms)","60 Years",{"count":485,"type":21},28,[151],"The prevalence of age-related chronic diseases (like obesity, type 2 diabetes and cardiovascular diseases) is mounting worldwide, reaching pandemic proportions. These age-related chronic diseases are associated with diminished skeletal muscle mitochondrial function in humans. Nicotinamide adenosine dinucleotide (NAD) is a coenzyme that regulates mitochondrial function, therefore, plays an important role in energy metabolism. Importantly, it has been shown that high cellular NAD+ levels as well as a high NAD+\u002FNADH ratio promote metabolic and mitochondrial health. In contrast, NAD+ bioavailability declines upon aging in humans as well as in animal models of metabolic disorders and type 2 diabetes. These findings fuel the notion of boosting the NAD+ bioavailability in order to improve metabolic disturbances and mitochondrial dysfunction in aged individuals. Supplementation with nicotinamide riboside (NR), a naturally occurring form of vitamin B3, boosts cellular NAD+ levels. However, in contrast to animal studies, NR supplementation in humans has so far been unsuccessful in improving skeletal muscle mitochondrial function, exercise capacity or insulin sensitivity. Interestingly, Recently, it has been suggested that metabolic conditions where NAD+ levels become limited, is needed for NR supplementation to exert beneficial health effects. This metabolic condition could be achieved by exercise. However, studies combining NR and exercise are lacking, and that is why we will perform the present study.",[489,490,28],"Healthy Aging","Lifestyle-related Condition","2025-07-08",{"date":493,"type":40},"2025-07-11",{"date":495,"type":40},"2024-03-01",{"date":497,"type":21},"2026-03",{"name":499,"class":47},"Finis Terrae University",{"id":501,"slug":502,"hasResults":11,"nctId":503,"briefTitle":504,"officialTitle":505,"acronym":4,"eligibilityCriteria":506,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":483,"enrollmentInfo":507,"targetDuration":4,"studyType":22,"phases":509,"briefSummary":510,"conditions":511,"keywords":513,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":517,"lastUpdatePostDateStruct":518,"startDateStruct":520,"completionDateStruct":522,"leadSponsor":524,"locationsCount":77},"100590499","phase-2-the-efficacy-and-safety-of-puerarin-in-obesity-treatment-100590499","NCT06968208","The Efficacy and Safety of Puerarin in Obesity Treatment","Randomized Controlled Trial of Puerarin for Obesity Treatment","Inclusion Criteria:\n\n1. Aged 18-60 years (inclusive), any gender.\n2. Obesity (BMI ≥30.0 kg\u002Fm²).\n3. With or without obesity-related metabolic comorbidities (e.g., type 2 diabetes, hypertension, dyslipidemia, hyperuricemia).\n4. No prior use of weight-control, glucose-lowering, or lipid-modifying medications.\n5. Stable weight (\\\u003C3% fluctuation) and lifestyle for ≥1 month prior to screening.\n6. Fully informed of trial objectives, procedures, risks, and benefits; voluntarily signed informed consent form.\n\nExclusion Criteria:\n\n1. Secondary causes of obesity (e.g., monogenic obesity, Cushing's syndrome, drug-induced obesity).\n2. History of common nutrient allergies (e.g., gluten, milk, eggs, plant-derived proteins).\n3. Use of weight-control medications (e.g., metformin, GLP-1 receptor agonists, orlistat), corticosteroids (oral\u002FIV\u002FIM\u002Fnon-oral systemic\u002Fintra-articular), or metabolic-interfering drugs\u002Fsupplements within 3 months prior to screening or during the trial.\n4. Use of traditional Chinese medicines or herbal products for weight management within 3 months prior to screening or during the trial.\n5. History of psychiatric disorders, epilepsy, antidepressant use, or ongoing antiepileptic therapy.\n6. Pregnancy, lactation, or plans for pregnancy within 6 months post-trial.\n7. Active infectious diseases (e.g., HBV, HCV, tuberculosis, syphilis, HIV).\n8. Severe infections, severe anemia (Hb \\\u003C8 g\u002FdL), or neutropenia (ANC \\\u003C1.5×10⁹\u002FL).\n9. Gastrointestinal surgery within 1 year (excluding appendectomy\u002Fhernia repair) or major non-GI surgery within 6 months.\n10. Active substance\u002Falcohol abuse.\n11. Known hypersensitivity to trial drug components or history of severe drug allergies.\n12. Severe cardiac disorders (e.g., congenital\u002Frheumatic heart disease, cardiomyopathy \\[NYHA ≥III\\], coronary stenting).\n13. Hyperthyroidism or hypothyroidism.\n14. History of malignancies (treated\u002Funtreated), regardless of recurrence status.\n15. Hepatic\u002Frenal dysfunction: ALT\u002FAST ≥2.5×ULN, serum creatinine \\>ULN, or eGFR \\\u003C60 mL\u002Fmin\u002F1.73m² (MDRD formula).\n16. Gastrointestinal disorders affecting absorption (e.g., IBD, active ulcers, severe diarrhea\u002Fconstipation).\n17. Participation in other clinical trials within 3 months prior to screening.\n18. Any condition deemed unsuitable by investigators.",{"count":508,"type":21},80,[24],"This randomized controlled trial aims to evaluate the therapeutic efficacy of puerarin intervention in weight management and metabolic regulation among obese populations. The study will systematically address two primary endpoints: 1) The capacity of puerarin to induce clinically significant body weight reduction in individuals with BMI ≥30 kg\u002Fm²; 2) Its modulatory effects on postprandial lipid metabolism as measured by serum lipids and quantitative fecal lipid excretion analysis. Secondary outcomes focus on puerarin's pleiotropic effects, including continuous glucose monitoring-derived glycemic parameters and indirect calorimetry-assessed resting metabolic rate. Secondary exploratory objectives include investigating puerarin's potential mechanisms of action through continuous glucose monitoring and indirect calorimetry measurements to assess glycemic variability and resting energy expenditure, respectively. Participants will be randomized into two parallel groups: the intervention group receiving daily oral puerarin injection (75 mg\u002Fday, dissolved in 100 mL of 0.9% sodium chloride solution) and the control group receiving matched blank 100 mL of 0.9% sodium chloride solution, both administered double-blind for 6 consecutive months. Primary efficacy endpoints (body weight, waist circumference, lipid profile) and safety monitoring (adverse events, hematological\u002F biochemical parameters) will be assessed at baseline, 1, 3, and 6 months post-intervention.",[28,512],"Obesity\u002FTherapy",[514,515,516],"Puerarin","Intestinal Lipid Absorption","Dorsal Motor Nucleus of Vagus (DMV)","2025-05-18",{"date":519,"type":40},"2025-05-21",{"date":521,"type":21},"2025-08-01",{"date":523,"type":21},"2029-12-31",{"name":525,"class":47},"Ruijin Hospital",{"id":527,"slug":528,"hasResults":11,"nctId":529,"briefTitle":530,"officialTitle":531,"acronym":532,"eligibilityCriteria":533,"healthyVolunteers":144,"sex":16,"minAge":17,"maxAge":331,"enrollmentInfo":534,"targetDuration":4,"studyType":22,"phases":536,"briefSummary":537,"conditions":538,"keywords":545,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":553,"lastUpdatePostDateStruct":554,"startDateStruct":556,"completionDateStruct":558,"leadSponsor":560,"locationsCount":77},"100590898","the-switch-dietary-and-behavioural-intervention-study-100590898","NCT06973408","The SWITCH Dietary and Behavioural Intervention Study","Switching to a Healthy and Sustainable Diet for Planetary and Human Health","SWITCH","Inclusion Criteria:\n\n* Age 18-70 years\n* Body mass index 25-35 kg\u002Fm2\n* Stable dietary patterns at the entry to the study (no specific dieting the last 4 weeks).\n* Willingness to adhere to advised diet pattern and to consume provided key foods.\n* Medications stable for the previous 14 days of relevant medicines\n* Access to a -18⁰ C freezer to store key foods at home.\n* Signed informed consent\n\nExclusion Criteria:\n\n* Currently having an infection or other relevant illness.\n* Cardiovascular events (myocardial infarction or stroke) during the previous 6 months. To be included, the disease needs to be stable.\n* Diagnosis of diabetes (any type).\n* Blood Pressure (BP): ≥185\u002F105 mmHg.\n* Serum Cholesterol (S-Chol): ≥8 mmol\u002FL.\n* Blood Glucose (B-Glucose): fasting value \\>7 mmol\u002FL.\n* Currently on GLP-1 receptor agonists.\n* History of stomach or gastrointestinal diagnoses (inflammatory bowel disease, Crohn's disease, hepatitis, malabsorption, celiac disease etc.).\n* IBS- if severe and recent (\\\u003C0.5year)?\n* Previous colostomy, bowel resection, bariatric surgery or other major gastrointestinal surgery.\n* Renal or liver failure (creatinine \\\u003C1.7 mg\u002Fdl and alanine aminotransferase\u002F aspartate aminotransferase \\> 2 times than normal values (ASAT, ALAT), respectively).\n* Anemia or Hemoglobin (Hb): \\\u003C100 g\u002FL\n* Blood donation (or participation in a clinical study with blood sampling) within 30 days prior to inclusion\n* Currently on a specific diet.\n* A diet incompatible with protocol diets such as strict vegan\u002Fvegetarian.\n* Food allergies or intolerances to food items included in the intervention.\n* High level of regular physical activity at baseline - scale 4 on SG-PALS.\n* History of drug or alcohol abuse.\n* Not able to understand written or spoken Swedish.\n* Any other reason for lack of suitability for participation in the trial, as judged by the principal investor and\u002F or the clinical investigator.\n* Pregnant or lactating or planning to become pregnant during the study period.\n* Involved in another potentially interfering research study.",{"count":535,"type":21},300,[151],"The overall objective of this study is to evaluate the effectiveness of an optimized lifestyle intervention based on dietary advice, behavioral support, and provision of key foods compared to dietary advice with behavioral support or dietary advice alone. The intervention aims to improve nutritional status, metabolic risk factors, and planetary sustainability.\n\nA total of 300 participants (150 men and 150 women) who meet all inclusion criteria and none of the exclusion criteria will be recruited. The study will be conducted at the Centre for Lifestyle Intervention at Östra Hospital in Gothenburg, led by researchers from Chalmers University of Technology, University of Gothenburg, and Sahlgrenska University Hospital. Participants will be recruited from two different socioeconomic areas in Gothenburg to examine how dietary interventions function in diverse population groups.\n\nThe study follows a twelve-week randomized, controlled, parallel intervention design. Participants will be randomized into three groups, each with 100 individuals:\n\nOptimized lifestyle intervention group - receiving dietary advice, behavioral support, and provision of key foods.\n\nBehavioral support intervention group - receiving dietary advice and behavioral support.\n\nControl group - receiving dietary advice according to the SWITCH diet. The SWITCH diet, developed within the EU project SWITCH, is designed to align with European dietary guidelines and promote sustainable and healthy eating habits. It emphasizes whole grains, vegetables, fruits, legumes, and sustainable seafood while limiting processed foods, added sugars, and salt.\n\nThroughout the study, participants will undergo clinical assessments at baseline, midpoint (week 7), and endpoint (week 13). Key measurements include anthropometric data, blood pressure, blood glucose, blood lipids, and inflammatory markers. Dietary intake and sustainability aspects of food consumption will also be evaluated. Participants in the intervention groups will receive personalized coaching and access to practical resources, such as meal plans, recipes, and visual educational materials.\n\nThe primary outcome of the study is the difference in cardiometabolic risk factors (e.g., blood lipids, blood pressure, glucose, insulin resistance markers) between the intervention groups. Secondary outcomes include changes in dietary intake, nutritional status markers, inflammatory markers, and sustainability measures (e.g., CO₂ emissions, land use, biodiversity impact). Additionally, exploratory analyses will investigate associations between diet, lifestyle changes, gut microbiota, and metabolic responses.\n\nThis study aims to generate valuable insights into the effectiveness of different dietary intervention strategies in real-life Nordic conditions. The results will contribute to the development of evidence-based recommendations for sustainable and health-promoting dietary patterns.",[539,540,541,28,542,543,544],"Dietary Behaviour","Dietary Intakes","Dietary Intervention","Blood Lipid Profiles","Blood Glucose Metabolism","Diet, Healthy",[546,176,547,548,549,550,551,552],"Cardiometabolic health","Dietary adherence","Sustainable diet","Nordic diet","Metabolic risk factors","Randomized controlled trial","nevironmental impact of diet","2025-05-14",{"date":555,"type":40},"2025-05-15",{"date":557,"type":40},"2025-03-03",{"date":559,"type":21},"2026-11-30",{"name":561,"class":47},"Chalmers University of Technology",{"id":563,"slug":564,"hasResults":11,"nctId":565,"briefTitle":566,"officialTitle":567,"acronym":568,"eligibilityCriteria":569,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":570,"targetDuration":197,"studyType":59,"phases":4,"briefSummary":572,"conditions":573,"keywords":576,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":583,"lastUpdatePostDateStruct":584,"startDateStruct":586,"completionDateStruct":588,"leadSponsor":590,"locationsCount":77},"100588329","cardiometabolic-evaluation-registry-of-heart-failure-100588329","NCT06939985","Cardiometabolic evalUation REgistry of Heart Failure","Cardiometabolic Risk Factors and Clinical Outcomes in Heart Failure: An Observational Cohort Study","CURE-HF","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Chronic HF (NYHA II\\~IV), including:\n\n   * HFrEF (HF with reduced ejection fraction): ① HF symptoms±signs ; ② LVEF≤40%.\n   * HFimpEF (HF with improved ejection fraction): ① HF symptoms±signs; ② previous LVEF ≤ 40% and a follow-up measurement of LVEF \\>40%.\n   * HFmrEF (HF with mildly reduced ejection fraction): ① HF symptoms±signs; ② LVEF 41%\\~49%.\n   * HFpEF (HF with preserved ejection fraction): ① HF symptoms±signs; ② LVEF ≥50%; ③ objective evidence of cardiac structural and\u002For functional abnormalities consistent with the presence of LV diastolic dysfunction\u002Fraised LV filling pressures, including raised natriuretic peptide.\n\nExclusion Criteria:\n\n1. Estimated survival ≤ 1 year.\n2. Pregnant or lactation, or have the intention to give birth within one year.\n3. Poor compliance, unable to follow-up.\n4. Mental or physical status not allowing written informed consent.\n5. Unwillingness to give informed consent.",{"count":571,"type":21},5000,"This is a combined retrospective-prospective observational cohort study investigating the role of systemic and local cardiometabolic risk factors in cardiac structural\u002Ffunctional remodeling and clinical outcomes among heart failure (HF) patients. The study integrates retrospective clinical data (from the past 10 years) and prospective longitudinal follow-up (5 years) of HF patients across HF with reduced (HFrEF), mildly-reduced (HFmrEF), preserved (HFpEF) and improved ejection fraction (HFimpEF) phenotypes. Systemic metabolic factors (e.g., blood lipid profiles, glycemic levels, insulin resistance) and local factors (e.g., epicardial adipose tissue \\[EAT\\], perivascular adipose tissue \\[PVAT\\]) will be analyzed for their associations with changes in cardiac geometrics and function, dynamic transitions between HF phenotypes, as well as the occurrence of major adverse cardiovascular events (MACEs). The study seeks to advance risk stratification by integrated evaluation of cardiometabolic profiles so as to refine personalized cures in HF management.",[574,575,28],"Heart Failure","Metabolic Cardiovascular Syndrome",[577,578,579,580,581,582],"heart failure","cardiometabolic risk factors","epicardial adipose tissue","cardiac remodeling","heart failure phenotypes","major adverse cardiovascular events","2025-04-18",{"date":585,"type":40},"2025-04-23",{"date":587,"type":40},"2015-01-01",{"date":589,"type":21},"2030-05-31",{"name":525,"class":47},{"id":592,"slug":593,"hasResults":11,"nctId":594,"briefTitle":595,"officialTitle":595,"acronym":4,"eligibilityCriteria":596,"healthyVolunteers":11,"sex":16,"minAge":597,"maxAge":194,"enrollmentInfo":598,"targetDuration":4,"studyType":22,"phases":600,"briefSummary":601,"conditions":602,"keywords":605,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":608,"lastUpdatePostDateStruct":609,"startDateStruct":611,"completionDateStruct":613,"leadSponsor":615,"locationsCount":77},"100583995","effect-of-low-valine-diet-on-body-weight-and-metabolic-parameters-100583995","NCT06883578","Effect of Low Valine Diet on Body Weight and Metabolic Parameters","Inclusion Criteria:\n\n* Male or female, 16 years old ≤ age ≤ 80 years old;\n* BMI ≥ 24kg\u002Fm2\n\nExclusion Criteria:\n\n* Excessive drinkers (defined as: in the past 6 months, the weekly alcohol intake of men exceeds 140g, and that of women exceeds 70g);\n* Liver diseases caused by other reasons: such as alcoholic liver disease, acute and chronic viral hepatitis, drug-induced, immune hepatitis (AMA, SMA, ANA), cirrhosis, liver cancer, etc.;\n* Other diseases that affect glucose and lipid metabolism: hyperthyroidism, hypothyroidism, Cushing's syndrome, etc.;\n* Poorly controlled diabetic patients: HbA1c \\>9.5% within three months; or use of hypoglycemic drugs that may affect weight, including pioglitazone, GLP-1, SGLT2 inhibitors;\n* Chronic kidney disease or severe renal impairment, defined as serum creatinine greater than 2.0mg\u002FdL;\n* Serum ALT greater than 3 times the upper limit of normal;\n* Life expectancy of no more than 3 years in the presence of serious health conditions;\n* Those who plan to get pregnant in the near future;\n* Those who cannot participate in the follow-up of the intervention due to other conditions;\n* Continuously used drugs that may cause weight changes for more than 2 weeks in the past year (such as glucocorticoids, thyroid hormones, etc.);\n* Participated in other clinical trials in the past 4 weeks;\n* Those who had gastric volume reduction surgery or digestive tract surgery;\n* Those diagnosed with any tumor disease;\n* Subjects who participated in strenuous exercise or planned to change their diet structure;\n* Unable to sign the informed consent form.","16 Years",{"count":599,"type":21},48,[151],"This study aimed to explore the effects of ordinary meal replacements and low-valine meal replacements on the weight and risk of related metabolic diseases in overweight\u002Fobese patients through a randomized double-blind controlled clinical trial.",[603,604,28],"Overweight\u002Fobesity","Metabolic Associated Fatty Liver Disease",[395,606,607],"Dietary intervention","Low valine meal replacement","2025-03-15",{"date":610,"type":40},"2025-03-19",{"date":612,"type":40},"2025-02-18",{"date":614,"type":21},"2026-04-30",{"name":616,"class":47},"Shanghai Zhongshan Hospital",{"id":618,"slug":619,"hasResults":11,"nctId":620,"briefTitle":621,"officialTitle":622,"acronym":623,"eligibilityCriteria":624,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":625,"targetDuration":4,"studyType":22,"phases":627,"briefSummary":628,"conditions":629,"keywords":646,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":652,"lastUpdatePostDateStruct":653,"startDateStruct":655,"completionDateStruct":656,"leadSponsor":658,"locationsCount":77},"100567960","clinical-trial-assessing-human-placental-membrane-products-and-standard-of-care-versus-standard-of-care-in-nonhealing-dfus-and-vlus-100567960","NCT06674980","Clinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DFUs and VLUs","A Multicenter, Prospective, Randomized Controlled Modified Platform Trial Assessing the Efficacy of Human Placental Membrane Products and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers.","C5CAMP","Inclusion Criteria for DFU:\n\n1. At least 18 years of age or older.\n2. Must have diagnosis of type 1 or 2 Diabetes mellitus.\n3. At enrollment, subject must have a target ulcer with a minimum surface area of 0.7 cm2 and a maximum surface area of 20.0 cm2 measured post debridement with the imaging device.\n4. Must have a target ulcer that has been present for a minimum of 4 weeks and maximum of 52 weeks of standard of care, prior to screening visit.\n5. Target ulcer located on the foot with at least 50% of the ulcer below the malleolus.\n6. Target ulcer that is Wagner 1 or 2 grade, extending at least through the dermis or subcutaneous tissue and may involve the muscle provided it is below the medial aspect of the malleolus. The ulcer may not include exposed tendon or bone.\n7. Subject's affected limb must have adequate perfusion confirmed by vascular assessment. Any of the following methods performed within 3 months of the first screening visit are acceptable:\n\n   1. ABI between 0.7 and \\\u003C= 1.3\n   2. TBI \\>= 0.6\n   3. TCOM \\>= 40 mmHg\n   4. PVR: biphasic\n8. If subject has two or more ulcers, they must be separated by 2 cm. The largest ulcer satisfying the inclusion and exclusion criteria will be designated as the target ulcer.\n9. Target ulcer must be located on the plantar aspect of the foot and must be offloaded for at least 14 days prior to enrollment.\n10. Subject must consent to using the prescribed offloading method for the duration of the study.\n11. Subject must agree to attend weekly study visits.\n12. Subject must be willing and able to participate in the consent process.\n\nExclusion Criteria for DFU:\n\n1. Subject is known to have a life expectancy of \\\u003C 6 months.\n2. Subject's target ulcer is not secondary to diabetes.\n3. Target ulcer is infected or there is cellulitis in the surrounding skin.\n4. Target ulcer exposes tendon or bone.\n5. Evidence of osteomyelitis complicating the target ulcer.\n6. Infection in the target ulcer or in a remote location that requires systemic antibiotic therapy.\n7. The subject is receiving immunosuppressants (including systemic corticosteroids at doses greater than 10 mg of prednisone per day or equivalent) or cytotoxic chemotherapy or is taking medications that the PI believes will interfere with wound healing (e.g., biologics).\n8. Subject is taking hydroxyurea.\n9. Subject has applied topical steroids to the ulcer surface within one month of initial screening.\n10. Subject has a previous partial amputation on the affected foot that results in a deformity that impedes proper offloading of the target ulcer.\n11. Subject has a glycated hemoglobin (HbA1c) greater than or equal to 12% within 3 months of the initial screening visit.\n12. The surface area of the subject's target ulcer has reduced in size by more than 20% in the 2 weeks prior to the initial screening visit (\"historical\" run-in period). Imaging Device is not required for measurements taken during the historical run-in period (e.g., calculating surface area using length X width is acceptable).\n13. The surface area measurement of the subject's target ulcer decreases by 20% or more during the active 2-week screening phase.\n14. Subject has acute Charcot foot, or an inactive Charcot foot, which impedes proper offloading of the target ulcer.\n15. Subject is a woman who is pregnant or considering becoming pregnant in the next 6 months.\n16. Subject has end stage renal disease requiring dialysis.\n17. Subject has participated in a clinical trial involving treatment with an investigational product within the previous 30 days.\n18. The subject, in opinion of the Investigator, has a medical or psychological condition that may interfere with study assessments.\n19. Subject was treated with hyperbaric oxygen therapy or a Cellular, Acellular, Matrix-like Product (CAMP) in the 30 days prior to screening.\n20. Subject has a malnutrition indicator score \\\u003C17 as measured on the Mini Nutritional Assessment.\n\nInclusion Criteria for VLU:\n\nPotential subjects are required to meet all the following criteria for enrollment in the study.\n\n1. Subjects must be at least 18 years of age or older.\n2. At randomization subjects must have a target ulcer with a minimum surface area of 0.7 cm2 and a maximum surface area of 20 cm2 measured post-debridement.\n3. The target ulcer must have been present for a minimum of 4 weeks and a maximum of 52 weeks of standard of care prior to the initial screening visit.\n4. No visible signs of healing objectively, less than 40% reduction in wound size in the last 4 weeks.\n5. The affected limb must have adequate perfusion confirmed by vascular assessment. Any of the following methods performed within 3 months of the first screening visit are acceptable:\n\n   1. ABI between 0.7 and ≤ 1.3;\n   2. TBI ≥ 0.6;\n   3. TCOM ≥ 40 mmHg;\n   4. PVR: biphasic.\n6. If the potential subject has two or more ulcers, they must be separated by at least 2 cm post-debridement. The largest ulcer satisfying the inclusion and exclusion criteria will be designated as the target ulcer.\n7. The potential subject must agree to attend the weekly study visits required by the protocol.\n8. The potential subject must be willing and able to participate in the informed consent process.\n\nExclusion Criteria for VLU:\n\n1. The potential subject is known to have a life expectancy of \\\u003C 6 months.\n2. The target ulcer is infected, requires systemic antibiotic therapy, or there is cellulitis in the surrounding skin.\n3. The target ulcer exposes tendon or bone.\n4. There is evidence of osteomyelitis complicating the target ulcer.\n5. The potential subject is receiving immunosuppressants (including systemic corticosteroids at doses greater than 10 mg of prednisone per day or equivalent) or cytotoxic chemotherapy or is taking medications that the PI believes will interfere with wound healing (e.g., biologics).\n6. The potential subject has applied topical steroids to the ulcer surface within one month of initial screening.\n7. The potential subject has glycated hemoglobin (HbA1c) greater than or equal to 12% within 3 months of the initial screening visit.\n8. The surface area of the target ulcer has reduced in size by more than 20% in the 2 weeks prior to the initial screening visit (\"historical\" run-in period). Imaging Device is not required for measurements taken during the historical run-in period (e.g., calculating surface area using length X width is acceptable).\n9. The surface area measurement of the target ulcer decreases by 20% or more during the active 2-week screening phase: the 2 weeks from the initial screening visit (SV-1) to the TV-1 visit during which time the potential subject received SOC.\n10. Women who are pregnant or considering becoming pregnant within the next 6 months.\n11. The potential subject has end stage renal disease requiring dialysis.\n12. Participation in a clinical trial involving treatment with an investigational product within the previous 30 days.\n13. A potential subject who, in the opinion of the investigator, has a medical or psychological condition that may interfere with study assessments.\n14. The potential subject was treated with hyperbaric oxygen therapy (HBOT) or a Cellular, Acellular, Matrix-like Product (CAMP) in the 30 days prior to the initial screening visit.\n15. The subject has a malnutrition indicator score \\\u003C17 as measured on the Mini Nutritional Assessment.\n16. A subject has a wound with active or latent infection is excluded.\n17. A subject with a disorder that would create unacceptable risk of post-operative complications is excluded.",{"count":626,"type":21},177,[151],"The purpose of the study is to evaluate the efficacy of multiple human placental membrane products and Standard of Care (SOC) versus SOC alone in the management of nonhealing diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs) over 12 weeks using a modified platform trial design.",[630,631,29,28,632,633,339,634,635,636,637,638,639,640,641,642,643,644,645],"Pathologic Processes","Diabetes Mellitus","Endocrine System Disease","Diabetic Angiopathies","Cardiovascular Diseases","Leg Ulcer","Skin Ulcer","Skin Diseases","Diabetes Complications","Diabetic Neuropathies","Foot Diseases","Diabetic Foot","Foot Ulcer","Diabetes Mellitus, Type 2","Ulcer","Foot Ulcer Unhealed",[647,648,649,650,651],"Human Placental Membrane (HPM)","Diabetic Foot Ulcer (DFU)","Venous Leg Ulcer (VLU)","Cellular, Acellular, and Matrix-like Product (CAMP)","Cellular and\u002For Tissue-Based Product (CTP)","2024-12-20",{"date":654,"type":40},"2024-12-27",{"date":652,"type":40},{"date":657,"type":21},"2027-01-22",{"name":659,"class":275},"C5 Biomedical",{"id":661,"slug":662,"hasResults":11,"nctId":663,"briefTitle":664,"officialTitle":664,"acronym":4,"eligibilityCriteria":665,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":224,"enrollmentInfo":666,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":668,"conditions":669,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":670,"lastUpdatePostDateStruct":671,"startDateStruct":673,"completionDateStruct":675,"leadSponsor":677,"locationsCount":77},"100556356","relationship-between-metabolic-profiles-and-chronic-diseases-and-neoplasms-100556356","NCT06524037","Relationship Between Metabolic Profiles and Chronic Diseases and Neoplasms","Inclusion Criteria:\n\n* adult aged ≥18 years old\n* Completed health screening\n\nExclusion Criteria:\n\n* aged \\\u003C18 years old\n* pregnancy",{"count":667,"type":21},2000,"Metabolic disorders are involved in the occurrence and development of a variety of chronic diseases and tumors. There are many common risk factors between chronic diseases and tumors. However, the mechanisms of chronic diseases and tumors caused by metabolic disorders are not completely clear. By observing the relationship between metabolic indexes and chronic diseases and tumors, the investigators intend to explore the possible mechanisms of metabolic status participating in the occurrence and development of chronic diseases and tumors.",[28],"2024-07-25",{"date":672,"type":40},"2024-07-29",{"date":674,"type":40},"2022-01-01",{"date":676,"type":21},"2032-12-31",{"name":678,"class":47},"First Affiliated Hospital of Chongqing Medical University"]